登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
A Clinical Study of of RN1701 Injection in the Treatment of Relapsed/Refractory B-Cell Lymphomas
ClinicalTrials.gov 上登记的一项淋巴瘤开放试验,由江苏大学附属医院牵头,本站收录的另外 0 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT07316920,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 8
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(8 项)收起清单
18 岁 至 75 岁;性别:不限
登记记录的入选字段
Histologically confirmed large B-cell lymphoma, follicular lymphoma, mantle-cell lymphoma, or indolent lymphoma transformed to DLBCL; CD19 and/or CD20 positive.
入选标准第 4 条
Large B-cell lymphoma, grade 3B follicular lymphoma, transformed indolent lymphoma: i. Primary refractory and ineligible/unable to receive autologous CAR-T: best response PD after ≥2 cycles of first-line therapy, or SD after ≥4 cycles.
入选标准第 7 条
Grade 1, 2, or 3A follicular lymphoma: i. Primary refractory and ineligible/unable to receive autologous CAR-T: best response PD after ≥2 cycles of first-line therapy.
入选标准第 8 条
Mantle-cell lymphoma: i. Primary refractory and ineligible/unable to receive autologous CAR-T: best response PD after ≥2 cycles of first-line therapy, or SD after ≥4 cycles.
入选标准第 9 条
Toxicities from prior anti-cancer therapy (except alopecia, nausea, and the above lab values) must have stabilized at baseline or resolved to ≤Grade 1.
入选标准第 19 条
Subjects of reproductive potential must use effective contraception for ≥12 months after completing study therapy.
入选标准第 21 条
Malignancy that received curative therapy and has shown no evidence of active disease for ≥2 years before enrolment; or
排除标准第 3 条
Major surgery within 2 weeks before screening or planned within 2 weeks after study treatment (local anaesthesia allowed).
排除标准第 35 条
ECOG performance status 0-1.
入选标准第 3 条
Hemoglobin ≥8.0 g/dL (no transfusion within 7 days).
入选标准第 12 条
Platelets ≥50×10⁹/L (no transfusion within 7 days).
入选标准第 13 条
ANC ≥1.0×10⁹/L (growth-factor support allowed if none within 7 days of test).
入选标准第 14 条
AST/ALT ≤3×ULN (≤5×ULN if liver involvement).
入选标准第 15 条
Serum creatinine ≤1.5×ULN or CrCl ≥60 mL/min (Cockcroft-Gault).
入选标准第 16 条
Total bilirubin ≤2×ULN (≤3×ULN if liver involvement); except congenital bilirubin disorders (e.g., Gilbert's syndrome: direct bilirubin ≤1.5×ULN).
入选标准第 17 条
INR, PT, APTT <1.5×ULN.
入选标准第 18 条
At least one measurable lesion per Lugano criteria: nodal lesion longest diameter >1.5 cm, extranodal lesion >1.0 cm.
入选标准第 5 条
Sum of the product of perpendicular diameters (SPD) of all measurable lesions ≥100 cm²;
排除标准第 17 条
Positive screen for HBsAg, HBeAg, HBV DNA, HCV antibody, HCV RNA, or HIV antibody.
排除标准第 36 条
WOCBP must have a negative high-sensitivity serum β-hCG pregnancy test at screening and again before the first dose of cyclophosphamide/fludarabine.
入选标准第 20 条
Lactating women.
排除标准第 38 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义)。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07316920,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Voluntary participation; full understanding of the study and provision of written informed consent obtained before any study-related procedure not part of standard care; willingness to comply with follow-up. Age 18-75 years; either sex. ECOG performance status 0-1. Histologically confirmed large B-cell lymphoma, follicular lymphoma, mantle-cell lymphoma, or indolent lymphoma transformed to DLBCL; CD19 and/or CD20 positive. At least one measurable lesion per Lugano criteria: nodal lesion longest diameter >1.5 cm, extranodal lesion >1.0 cm. Prior treatment response must meet one of the following: Large B-cell lymphoma, grade 3B follicular lymphoma, transformed indolent lymphoma: i. Primary refractory and ineligible/unable to receive autologous CAR-T: best response PD after ≥2 cycles of first-line therapy, or SD after ≥4 cycles. Grade 1, 2, or 3A follicular lymphoma: i. Primary refractory and ineligible/unable to receive autologous CAR-T: best response PD after ≥2 cycles of first-line therapy. Mantle-cell lymphoma: i. Primary refractory and ineligible/unable to receive autologous CAR-T: best response PD after ≥2 cycles of first-line therapy, or SD after ≥4 cycles. Estimated life expectancy ≥3 months. Screening laboratory values (may be repeated once): Hemoglobin ≥8.0 g/dL (no transfusion within 7 days). Platelets ≥50×10⁹/L (no transfusion within 7 days). ANC ≥1.0×10⁹/L (growth-factor support allowed if none within 7 days of test). AST/ALT ≤3×ULN (≤5×ULN if liver involvement). Serum creatinine ≤1.5×ULN or CrCl ≥60 mL/min (Cockcroft-Gault). Total bilirubin ≤2×ULN (≤3×ULN if liver involvement); except congenital bilirubin disorders (e.g., Gilbert's syndrome: direct bilirubin ≤1.5×ULN). INR, PT, APTT <1.5×ULN. Toxicities from prior anti-cancer therapy (except alopecia, nausea, and the above lab values) must have stabilized at baseline or resolved to ≤Grade 1. WOCBP must have a negative high-sensitivity serum β-hCG pregnancy test at screening and again before the first dose of cyclophosphamide/fludarabine. Subjects of reproductive potential must use effective contraception for ≥12 months after completing study therapy.排除标准:Exclusion Criteria:
Subjects with any of the following conditions are ineligible for this trial: Any malignancy other than B-cell non-Hodgkin lymphoma ever diagnosed or treated, except: Malignancy that received curative therapy and has shown no evidence of active disease for ≥2 years before enrolment; or Adequately treated non-melanoma skin cancer with no current evidence of disease. Prior anti-cancer therapy within the stated windows (before lymphodepletion): CNS prophylaxis (e.g., intrathecal methotrexate and/or cytarabine) within 7 days; Cytotoxic chemotherapy or radiotherapy within 14 days; Small-molecule targeted or epigenetic therapy within 14 days or 5 half-lives, whichever is longer; Monoclonal antibody, bispecific antibody, or antibody-drug conjugate within 21 days or 5 half-lives, whichever is shorter; Investigational drug or invasive investigational device within 28 days (if the therapy is also investigational, the 28-day wash-out applies); Autologous haematopoietic stem-cell transplant or CD19-directed autologous CAR-T therapy within 100 days. Any autologous cellular or gene therapy other than CD19-directed autologous CAR-T. Any allogeneic cellular (including CAR-T) or gene therapy. Prior allogeneic haematopoietic stem-cell transplantation. Positive donor-specific antibody (DSA). At least one of the following high-risk features: Sum of the product of perpendicular diameters (SPD) of all measurable lesions ≥100 cm²; Bulky disease: single mass ≥7.5 cm; mediastinal mass with maximum diameter >1/3 of thoracic diameter; Obstructive/compressive emergency (e.g., bowel obstruction, vascular compression) requiring urgent intervention at screening. Active CNS involvement (symptomatic or positive CSF/imaging); subjects with prior CNS disease now in remission (asymptomatic with negative CSF and imaging) are eligible. Significant bleeding diathesis: gastrointestinal bleeding, haemorrhagic cystitis, coagulopathy, hypersplenism (splenomegaly on exam/US, cytopenias, hyperplastic marrow) or ongoing anticoagulation. Chronic concomitant systemic corticosteroids or other immunosuppressants, except: topical, ocular, intra-articular, nasal or inhaled corticosteroids; short-course steroids for prophylaxis (e.g., contrast allergy). Severe underlying medical conditions: Active serious viral, bacterial or uncontrolled systemic fungal infection; Active systemic autoimmune disease requiring therapy. Significant cardiac disease: NYHA class III or IV congestive heart failure; Myocardial infarction or CABG within 6 months before enrolment; Clinically relevant ventricular arrhythmia or unexplained syncope not vasovagal or dehydration-related; Severe non-ischaemic cardiomyopathy; Left ventricular ejection fraction (LVEF) <45% by echo or MUGA within 4 weeks before lymphodepletion. Resting oxygen saturation <92%. Clinically relevant prior or current CNS disorder: epilepsy, seizure-like episodes, paralysis, aphasia, stroke, severe head trauma, dementia, Parkinson's disease, cerebellar disorder, organic brain syndrome or major psychiatric illness. Live-attenuated vaccine within 4 weeks before screening. Major surgery within 2 weeks before screening or planned within 2 weeks after study treatment (local anaesthesia allowed). Positive screen for HBsAg, HBeAg, HBV DNA, HCV antibody, HCV RNA, or HIV antibody. Life-threatening allergy, hypersensitivity or intolerance to study-drug excipients including, but not limited to, DMSO. Lactating women. Any condition that, in the investigator's opinion, renders the subject unsuitable for the study.
引自 ClinicalTrials.gov, NCT07316920, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07316920,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。